Inventiva (NASDAQ:IVA) Sets New 12-Month Low - Time to Sell?

Key Points

• Inventiva shares fell 7.4% to a new 52-week low, trading as low as $3.31 and below both their 50-day and 200-day moving averages.
• Despite the decline, Wall Street sentiment remains positive overall: analysts maintain a consensus “Buy” rating with an average price target of $15.75, although Weiss Ratings issued a “sell” rating.
• Institutional interest has increased, with hedge funds and other institutions owning 19.06% of the stock; the company’s key development program is lanifibranor, a late-stage treatment candidate for MASH.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $3.31 and last traded at $3.2460, with a volume of 194757 shares changing hands. The stock had previously closed at $3.45.

Wall Street Analysts Forecast Growth

IVA has been the topic of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inventiva in a research report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a report on Friday, July 17th. They set an "overweight" rating on the stock. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research report on Wednesday, September 16th. Finally, Guggenheim upped their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, September 15th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Inventiva currently has a consensus rating of "Buy" and an average target price of $15.75.

Inventiva Trading Down 7.4%

The stock's 50-day simple moving average is $4.47 and its 200-day simple moving average is $4.79.

Hedge Funds Weigh In On Inventiva

Several large investors have recently made changes to their positions in IVA. Engineers Gate Manager LP raised its holdings in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after purchasing an additional 43,280 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Inventiva in the first quarter worth about $1,111,000. Persistent Asset Partners Ltd purchased a new stake in Inventiva in the fourth quarter worth about $603,000. NEXTBio Capital Management LP purchased a new stake in Inventiva in the fourth quarter worth about $6,039,000. Finally, Eventide Asset Management LLC bought a new position in shares of Inventiva in the fourth quarter worth about $1,155,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.